Biological and clinical characteristics of patients with chronic lymphocytic leukemia with the IGHV3-21 and IGHV1-69; analysis of data from a single center
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33154253" target="_blank" >RIV/61989592:15110/15:33154253 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/61989592:15510/15:33154253 RIV/00098892:_____/15:#0000924
Výsledek na webu
<a href="http://dx.doi.org/10.4149/neo_2015_074" target="_blank" >http://dx.doi.org/10.4149/neo_2015_074</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2015_074" target="_blank" >10.4149/neo_2015_074</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Biological and clinical characteristics of patients with chronic lymphocytic leukemia with the IGHV3-21 and IGHV1-69; analysis of data from a single center
Popis výsledku v původním jazyce
This study aimed at mapping the frequency of IGHV3-21 and IGHV1-69 in a group of 417 patients newly diagnosed with chronic lymphocytic leukemia (CLL) and described basic characteristics, cytogenetic abnormalities and prognosis of these patient subgroups.IGHV3-21 was found in 29 patients (7%) and IGHV1-69 in 51 patients (12.4%). The median overall survival (OS) rates were 97 months and 85 months in the IGHV3-21 and IGHV1-69 groups, respectively. In this small group of patients, the study failed to showa difference in OS of IGHV3-21 patients with mutated and unmutated IGHV status (p<0.597). There was also no difference in OS between IGHV3-21 patients with mutated IGHV status and all patients in the group having unmutated IGHV status (p<0.245). On the other hand, patients with IGHV3-21 and the presence of some other adverse prognostic factors (age GREATER-THAN OR EQUAL TO 65 years, lymphocyte count GREATER-THAN OR EQUAL TO 50x109/L, serum thymidine kinase GREATER-THAN OR EQUAL TO 9U/L,
Název v anglickém jazyce
Biological and clinical characteristics of patients with chronic lymphocytic leukemia with the IGHV3-21 and IGHV1-69; analysis of data from a single center
Popis výsledku anglicky
This study aimed at mapping the frequency of IGHV3-21 and IGHV1-69 in a group of 417 patients newly diagnosed with chronic lymphocytic leukemia (CLL) and described basic characteristics, cytogenetic abnormalities and prognosis of these patient subgroups.IGHV3-21 was found in 29 patients (7%) and IGHV1-69 in 51 patients (12.4%). The median overall survival (OS) rates were 97 months and 85 months in the IGHV3-21 and IGHV1-69 groups, respectively. In this small group of patients, the study failed to showa difference in OS of IGHV3-21 patients with mutated and unmutated IGHV status (p<0.597). There was also no difference in OS between IGHV3-21 patients with mutated IGHV status and all patients in the group having unmutated IGHV status (p<0.245). On the other hand, patients with IGHV3-21 and the presence of some other adverse prognostic factors (age GREATER-THAN OR EQUAL TO 65 years, lymphocyte count GREATER-THAN OR EQUAL TO 50x109/L, serum thymidine kinase GREATER-THAN OR EQUAL TO 9U/L,
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Neoplasma
ISSN
0028-2685
e-ISSN
—
Svazek periodika
62
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
SK - Slovenská republika
Počet stran výsledku
9
Strana od-do
618-626
Kód UT WoS článku
000362862500013
EID výsledku v databázi Scopus
—